Furosemide and Calcium Pyrophosphate Deposition Disease (CPPD)

Mechanism of Furosemide's Impact on CPPD

Magnesium depletion caused by furosemide can promote CPP crystal formation and deposition, as magnesium can solubilize CPP crystals and has inhibitory effects on nucleation and growth of these crystals 3

Furosemide administration has been associated with potential side effects including magnesium depletion, which can increase calcium excretion, according to the American Thoracic Society 1, 4
In vitro studies have demonstrated that magnesium can solubilize CPP crystals and inhibit their formation, as reported by the European League Against Rheumatism 3
The precipitation of acute CPP crystal arthritis has been reported following magnesium depletion, as noted by the European League Against Rheumatism 3
Benefit of magnesium replacement has been reported in a patient with hypomagnesemia and chondrocalcinosis, according to the European League Against Rheumatism 3

For patients requiring diuretic therapy who have CPPD, consider alternative diuretics with less impact on magnesium levels when possible, as recommended by the American College of Chest Physicians 2
Consider magnesium supplementation in patients with CPPD who must receive furosemide, as suggested by the European League Against Rheumatism 3

First-line options for CPPD management include NSAIDs with gastroprotection for acute attacks, colchicine for prophylaxis or chronic inflammatory arthritis, and joint aspiration with corticosteroid injection for acute attacks, as recommended by the European League Against Rheumatism 5
If diuretic therapy is necessary, consider supplementing magnesium, though evidence for its effectiveness in reducing radiographic chondrocalcinosis is limited, as noted by the European League Against Rheumatism 3

Unlike gout, there are currently no specific treatments to eliminate CPP crystals, making prevention of crystal formation particularly important, as reported by the European League Against Rheumatism 5